CTI BioPharma Corp (CTIC) – Strategy, SWOT and Corporate Finance Report

CTI BioPharma Corp (CTIC) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company that acquires, develops, and commercializes novel therapies for a range of blood-related cancers. Its lead product, Pacritinib is intended for the treatment of patients with myeloproliferative diseases. Its product pipeline includes PACIFICA for the treatment of myelofibrosis patients with severe thrombocytopenia; PAC203 for the patients with ruxolitinib therapy failure; PRE-VENT for COVID-19; PERSIST 1 for all platelets count and PERSIST 2 for platelets counts less than thousand. The company’s commercialized product, Vonjo is targeted for the treatment of adult patients with myelofibrosis patients with severe thrombocytopenia. The company relies on third parties for manufacturing and marketing its products. CTI BioPharma is headquartered in Seattle, Washington, the US.

Scope

• Detailed information on CTI BioPharma Corp required for business and competitor intelligence needs

• A study of the major internal and external factors affecting CTI BioPharma Corp in the form of a SWOT analysis

• An in-depth view of the business model of CTI BioPharma Corp including a breakdown and examination of key business segments

• News about CTI BioPharma Corp, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of CTI BioPharma Corp and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess CTI BioPharma Corp as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on CTI BioPharma Corps business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Clovis Oncology Inc

Bristol-Myers Squibb Co

Geron Corp

Novartis AG

Johnson & Johnson

Incyte Corp

Clovis Oncology Inc

Novartis AG

Incyte Corp

Geron Corp

Bristol-Myers Squibb Co

Johnson & Johnson

Table of Contents

Table of Contents

List of Figures

Section 1 - About the Company

CTI BioPharma Corp - Key Facts

CTI BioPharma Corp - Key Employees

CTI BioPharma Corp - Key Employee Biographies

CTI BioPharma Corp - Major Products and Services

CTI BioPharma Corp - History

CTI BioPharma Corp - Company Statement

CTI BioPharma Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

CTI BioPharma Corp - Business Description

CTI BioPharma Corp - Corporate Strategy

CTI BioPharma Corp - SWOT Analysis

SWOT Analysis - Overview

CTI BioPharma Corp - Strengths

CTI BioPharma Corp - Weaknesses

CTI BioPharma Corp - Opportunities

CTI BioPharma Corp - Threats

CTI BioPharma Corp - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

CTI BioPharma Corp, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 30, 2023: CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

Mar 06, 2023: CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 23, 2023: CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023

Sep 21, 2022: CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology Tenth Annual Meeting

Aug 08, 2022: CTI BioPharma Reports Second Quarter 2022 Financial Results

Aug 01, 2022: CTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022

May 12, 2022: CTI BioPharma Reports First Quarter 2022 Financial Results

May 10, 2022: CTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Mar 31, 2022: CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

CTI BioPharma Corp, Key Facts

CTI BioPharma Corp, Key Employees

CTI BioPharma Corp, Key Employee Biographies

CTI BioPharma Corp, Major Products and Services

CTI BioPharma Corp, History

CTI BioPharma Corp, Subsidiaries

CTI BioPharma Corp, Key Competitors

CTI BioPharma Corp, Ratios based on current share price

CTI BioPharma Corp, Annual Ratios

CTI BioPharma Corp, Annual Ratios (Cont…1)

CTI BioPharma Corp, Annual Ratios (Cont…2)

CTI BioPharma Corp, Interim Ratios

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

CTI BioPharma Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

CTI BioPharma Corp, Performance Chart (2018 – 2022)

CTI BioPharma Corp, Ratio Charts

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports